ATE282416T1 - Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen - Google Patents

Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen

Info

Publication number
ATE282416T1
ATE282416T1 AT97952023T AT97952023T ATE282416T1 AT E282416 T1 ATE282416 T1 AT E282416T1 AT 97952023 T AT97952023 T AT 97952023T AT 97952023 T AT97952023 T AT 97952023T AT E282416 T1 ATE282416 T1 AT E282416T1
Authority
AT
Austria
Prior art keywords
treatment
receptor antagonists
disorders
substance
substance use
Prior art date
Application number
AT97952023T
Other languages
English (en)
Inventor
Raymond Baker
Neil Roy Curtis
Jason Matthew Elliott
Timothy Harrison
Gregory John Hollingworth
Philip Stephen Jackson
Janusz Jozef Kulagowski
Nadia Melanie Rupniak
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE282416(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9625051A external-priority patent/GB9625051D0/en
Priority claimed from GB9701459A external-priority patent/GB9701459D0/en
Priority claimed from GB9713715A external-priority patent/GB9713715D0/en
Priority claimed from GBGB9717097.1A external-priority patent/GB9717097D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE282416T1 publication Critical patent/ATE282416T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97952023T 1996-12-02 1997-11-25 Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen ATE282416T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
GB9701459A GB9701459D0 (en) 1997-01-24 1997-01-24 Therapeutic agents
GB9713715A GB9713715D0 (en) 1997-06-27 1997-06-27 Therapeutic agents
GBGB9717097.1A GB9717097D0 (en) 1997-08-12 1997-08-12 Therapeutic agents
PCT/EP1997/006690 WO1998024444A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating substance use disorders

Publications (1)

Publication Number Publication Date
ATE282416T1 true ATE282416T1 (de) 2004-12-15

Family

ID=27451570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97952023T ATE282416T1 (de) 1996-12-02 1997-11-25 Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen

Country Status (9)

Country Link
US (1) US5919781A (de)
EP (1) EP0942731B1 (de)
JP (1) JP2001504853A (de)
AT (1) ATE282416T1 (de)
AU (1) AU731674B2 (de)
CA (1) CA2273806A1 (de)
DE (1) DE69731657T2 (de)
ES (1) ES2231901T3 (de)
WO (1) WO1998024444A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271230B1 (en) * 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
CA2334609A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
JP2002517446A (ja) * 1998-06-11 2002-06-18 メルク シャープ エンド ドーム リミテッド 精神障害の治療のためのnk−1受容体アンタゴニストの使用
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier
US20050065175A1 (en) * 2003-09-24 2005-03-24 Xanodyne Pharmacal, Inc. Oral transmucosal methadone
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU6226494A (en) * 1993-03-04 1994-09-26 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
HU221139B1 (en) * 1993-12-29 2002-08-28 Merck Sharp & Dohme Tachykinin antagonist substituted morpholine derivatives, preparation and use thereof
AU691327B2 (en) * 1994-08-15 1998-05-14 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents
GB9426103D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders

Also Published As

Publication number Publication date
DE69731657D1 (de) 2004-12-23
AU731674B2 (en) 2001-04-05
US5919781A (en) 1999-07-06
DE69731657T2 (de) 2005-12-01
ES2231901T3 (es) 2005-05-16
AU5559398A (en) 1998-06-29
JP2001504853A (ja) 2001-04-10
WO1998024444A1 (en) 1998-06-11
CA2273806A1 (en) 1998-06-11
EP0942731B1 (de) 2004-11-17
EP0942731A1 (de) 1999-09-22

Similar Documents

Publication Publication Date Title
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
ATE177095T1 (de) Substituierte piperidine für die behandlung von allergischen krankheiten
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
DE69821132T2 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
EP0548250A4 (en) Substituted bicyclic aryl compounds exhibiting selective leukotriene b 4? antagonist activity
DE59810761D1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
NO994850L (no) Farmakologiske midler
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
NO975975L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
NZ300942A (en) 1-aryl-2-acylamino-ethane derivatives as neurokinin 1 antagonists
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
SE9903995D0 (sv) New combination
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE293975T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen
DE69732133D1 (de) Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen
DE69732492D1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
DE69730515D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
UA27715C2 (uk) Похідні лактаму та фармацевтична композиція, яка є антагоністом 5-окситриптоміну /5-нт/ на 5-нт рецепторах

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0942731

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked